Wedbush Maintains Neutral on NovoCure, Raises Price Target to $20
Wedbush analyst David Nierengarten maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $18 to $20.
Read original at benzingaStocks · News reference
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and planned trial savings.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 24, 2026, 3:08 PM
- Checked
- Jul 24, 2026, 3:08 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52
HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $46 to $52.
Read original at benzingaCrude Oil Rises Sharply; T-Mobile Shares Fall Following Q2 Results
US stocks lower, Dow down 0.92%, NASDAQ 2.03% decline. T-Mobile stock falls 5%. NVE Corp up 38%, Novocure up 25%, Cleveland-Cliffs up 19%
Read original at benzinga